Role of enhanced arachidonate availability through phospholipase A2 pathway in mediation of increased prostaglandin synthesis by glomeruli from diabetic rats

P. A. Craven, M. C. Patterson, F. R. DeRubertis

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Prostaglandin E2 (PGE2) production by superfused glomeruli from rats made diabetic for 2 wk by streptozocin injection is twofold higher than that by glomeruli from normal rats. The higher rates of PGE2 production by glomeruli from diabetic rats are associated with higher levels of labeled free arachidonate in glomeruli prelabeled with [3H]arachidonate, both basally and after stimulation with Ca2+ ionophore A23187. The difference between release of labeled arachidonate from phospholipids of diabetic versus normal glomeruli is likely underestimated by measurements of arachidonate alone due to more rapid incorporation of released arachidonate into triacylglycerol of diabetic glomeruli. A23187 induced a fall in labeled phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol in glomeruli that had been prelabeled with [3H]arachidonate and also induced a reduction in the mass of these phospholipids. Consistent with the higher levels of labeled arachidonate, the reduction in both labeled phospholipids and phospholipid mass with A23187 was greater in glomeruli from diabetic than normal rats. Furthermore, the reduction in labeled phospholipids and phospholipid mass with A23187 was largely (62-80%) accounted for by a fall in phosphatidylcholine plus phosphatidylethanolamine in glomeruli from both normal and diabetic rats. These results suggest a primary role for phospholipase A2 in A23187 actions on glomerular arachidonate release in normal rats and for the higher levels of arachidonate found in glomeruli from diabetic rats. Nevertheless, A23187 also stimulated the production of inositol phosphates - a measure of cellular phospholipase C activity. The increases in inositol phosphate production induced by A23187 were greater in glomeruli from diabetic than normal rats. However, the difference in inositol phosphate production between the two groups was abolished by indomethacin, suggesting that they were secondary to the enhanced prostanoid production by the diabetic glomeruli. Studies of phospholipase A2 and C activities in subcellular fractions of glomerular homogenates also supported a role for enhanced phospholipase A2 activity in the mediation of increased availability of arachidonate for prostaglandin synthesis in glomeruli from diabetic versus normal rats. Thus, phospholipase A2 activity was twofold higher in glomeruli from diabetic than normal rats, whereas phospholipase C activity was not different between the two groups. Treatment of diabetic rats with insulin prevented the rise in glomerular phospholipid A2 otherwise seen in these rats.

Original languageEnglish (US)
Pages (from-to)429-435
Number of pages7
JournalDiabetes
Volume37
Issue number4
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Phospholipases A2
Prostaglandins
Calcimycin
Phospholipids
Inositol Phosphates
Type C Phospholipases
Phosphatidylcholines
Dinoprostone
Subcellular Fractions
Ionophores
Streptozocin
Phosphatidylinositols
varespladib methyl
Indomethacin
Triglycerides
Insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Role of enhanced arachidonate availability through phospholipase A2 pathway in mediation of increased prostaglandin synthesis by glomeruli from diabetic rats. / Craven, P. A.; Patterson, M. C.; DeRubertis, F. R.

In: Diabetes, Vol. 37, No. 4, 01.01.1988, p. 429-435.

Research output: Contribution to journalArticle

@article{98e53ee476a548ed9395f4c50d45dca5,
title = "Role of enhanced arachidonate availability through phospholipase A2 pathway in mediation of increased prostaglandin synthesis by glomeruli from diabetic rats",
abstract = "Prostaglandin E2 (PGE2) production by superfused glomeruli from rats made diabetic for 2 wk by streptozocin injection is twofold higher than that by glomeruli from normal rats. The higher rates of PGE2 production by glomeruli from diabetic rats are associated with higher levels of labeled free arachidonate in glomeruli prelabeled with [3H]arachidonate, both basally and after stimulation with Ca2+ ionophore A23187. The difference between release of labeled arachidonate from phospholipids of diabetic versus normal glomeruli is likely underestimated by measurements of arachidonate alone due to more rapid incorporation of released arachidonate into triacylglycerol of diabetic glomeruli. A23187 induced a fall in labeled phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol in glomeruli that had been prelabeled with [3H]arachidonate and also induced a reduction in the mass of these phospholipids. Consistent with the higher levels of labeled arachidonate, the reduction in both labeled phospholipids and phospholipid mass with A23187 was greater in glomeruli from diabetic than normal rats. Furthermore, the reduction in labeled phospholipids and phospholipid mass with A23187 was largely (62-80{\%}) accounted for by a fall in phosphatidylcholine plus phosphatidylethanolamine in glomeruli from both normal and diabetic rats. These results suggest a primary role for phospholipase A2 in A23187 actions on glomerular arachidonate release in normal rats and for the higher levels of arachidonate found in glomeruli from diabetic rats. Nevertheless, A23187 also stimulated the production of inositol phosphates - a measure of cellular phospholipase C activity. The increases in inositol phosphate production induced by A23187 were greater in glomeruli from diabetic than normal rats. However, the difference in inositol phosphate production between the two groups was abolished by indomethacin, suggesting that they were secondary to the enhanced prostanoid production by the diabetic glomeruli. Studies of phospholipase A2 and C activities in subcellular fractions of glomerular homogenates also supported a role for enhanced phospholipase A2 activity in the mediation of increased availability of arachidonate for prostaglandin synthesis in glomeruli from diabetic versus normal rats. Thus, phospholipase A2 activity was twofold higher in glomeruli from diabetic than normal rats, whereas phospholipase C activity was not different between the two groups. Treatment of diabetic rats with insulin prevented the rise in glomerular phospholipid A2 otherwise seen in these rats.",
author = "Craven, {P. A.} and Patterson, {M. C.} and DeRubertis, {F. R.}",
year = "1988",
month = "1",
day = "1",
doi = "10.2337/diab.37.4.429",
language = "English (US)",
volume = "37",
pages = "429--435",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Role of enhanced arachidonate availability through phospholipase A2 pathway in mediation of increased prostaglandin synthesis by glomeruli from diabetic rats

AU - Craven, P. A.

AU - Patterson, M. C.

AU - DeRubertis, F. R.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Prostaglandin E2 (PGE2) production by superfused glomeruli from rats made diabetic for 2 wk by streptozocin injection is twofold higher than that by glomeruli from normal rats. The higher rates of PGE2 production by glomeruli from diabetic rats are associated with higher levels of labeled free arachidonate in glomeruli prelabeled with [3H]arachidonate, both basally and after stimulation with Ca2+ ionophore A23187. The difference between release of labeled arachidonate from phospholipids of diabetic versus normal glomeruli is likely underestimated by measurements of arachidonate alone due to more rapid incorporation of released arachidonate into triacylglycerol of diabetic glomeruli. A23187 induced a fall in labeled phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol in glomeruli that had been prelabeled with [3H]arachidonate and also induced a reduction in the mass of these phospholipids. Consistent with the higher levels of labeled arachidonate, the reduction in both labeled phospholipids and phospholipid mass with A23187 was greater in glomeruli from diabetic than normal rats. Furthermore, the reduction in labeled phospholipids and phospholipid mass with A23187 was largely (62-80%) accounted for by a fall in phosphatidylcholine plus phosphatidylethanolamine in glomeruli from both normal and diabetic rats. These results suggest a primary role for phospholipase A2 in A23187 actions on glomerular arachidonate release in normal rats and for the higher levels of arachidonate found in glomeruli from diabetic rats. Nevertheless, A23187 also stimulated the production of inositol phosphates - a measure of cellular phospholipase C activity. The increases in inositol phosphate production induced by A23187 were greater in glomeruli from diabetic than normal rats. However, the difference in inositol phosphate production between the two groups was abolished by indomethacin, suggesting that they were secondary to the enhanced prostanoid production by the diabetic glomeruli. Studies of phospholipase A2 and C activities in subcellular fractions of glomerular homogenates also supported a role for enhanced phospholipase A2 activity in the mediation of increased availability of arachidonate for prostaglandin synthesis in glomeruli from diabetic versus normal rats. Thus, phospholipase A2 activity was twofold higher in glomeruli from diabetic than normal rats, whereas phospholipase C activity was not different between the two groups. Treatment of diabetic rats with insulin prevented the rise in glomerular phospholipid A2 otherwise seen in these rats.

AB - Prostaglandin E2 (PGE2) production by superfused glomeruli from rats made diabetic for 2 wk by streptozocin injection is twofold higher than that by glomeruli from normal rats. The higher rates of PGE2 production by glomeruli from diabetic rats are associated with higher levels of labeled free arachidonate in glomeruli prelabeled with [3H]arachidonate, both basally and after stimulation with Ca2+ ionophore A23187. The difference between release of labeled arachidonate from phospholipids of diabetic versus normal glomeruli is likely underestimated by measurements of arachidonate alone due to more rapid incorporation of released arachidonate into triacylglycerol of diabetic glomeruli. A23187 induced a fall in labeled phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol in glomeruli that had been prelabeled with [3H]arachidonate and also induced a reduction in the mass of these phospholipids. Consistent with the higher levels of labeled arachidonate, the reduction in both labeled phospholipids and phospholipid mass with A23187 was greater in glomeruli from diabetic than normal rats. Furthermore, the reduction in labeled phospholipids and phospholipid mass with A23187 was largely (62-80%) accounted for by a fall in phosphatidylcholine plus phosphatidylethanolamine in glomeruli from both normal and diabetic rats. These results suggest a primary role for phospholipase A2 in A23187 actions on glomerular arachidonate release in normal rats and for the higher levels of arachidonate found in glomeruli from diabetic rats. Nevertheless, A23187 also stimulated the production of inositol phosphates - a measure of cellular phospholipase C activity. The increases in inositol phosphate production induced by A23187 were greater in glomeruli from diabetic than normal rats. However, the difference in inositol phosphate production between the two groups was abolished by indomethacin, suggesting that they were secondary to the enhanced prostanoid production by the diabetic glomeruli. Studies of phospholipase A2 and C activities in subcellular fractions of glomerular homogenates also supported a role for enhanced phospholipase A2 activity in the mediation of increased availability of arachidonate for prostaglandin synthesis in glomeruli from diabetic versus normal rats. Thus, phospholipase A2 activity was twofold higher in glomeruli from diabetic than normal rats, whereas phospholipase C activity was not different between the two groups. Treatment of diabetic rats with insulin prevented the rise in glomerular phospholipid A2 otherwise seen in these rats.

UR - http://www.scopus.com/inward/record.url?scp=0023948928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023948928&partnerID=8YFLogxK

U2 - 10.2337/diab.37.4.429

DO - 10.2337/diab.37.4.429

M3 - Article

C2 - 3132411

AN - SCOPUS:0023948928

VL - 37

SP - 429

EP - 435

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 4

ER -